{"disease":{"id":"late-infantile-neuronal-ceroid-lipofuscinosis","name":"Late-infantile neuronal ceroid lipofuscinosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cerliponase-alfa","indication_name":"Late-infantile neuronal ceroid lipofuscinosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhttp1","generic_name":"CERLIPONASE ALFA","company_name":"BioMarin","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase","quality_score":10,"revenue":null,"mechanism":"Cerliponase alfa works by inhibiting the breakdown of a protein called tripeptidyl peptidase, which is deficient in patients with late-infantile neuronal ceroid lipofuscinosis."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT04476862","title":"Cerliponase Alfa Observational Study in the US","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT02678689","title":"A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":true},{"nct_id":"NCT01161576","title":"Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT01414985","title":"AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}